Global Orphan Cancer Drug Market, Drug Sales, Price & Clinical Trials Insight 2028 Report Highlights:
- Global Orphan Designated Cancer Drug Market Opportunity > USD 150 Billion by 2028
- Global & Regional Market Size 2022 Till 2028
- Market Size By Orphan Designated Cancer Type 2022 Till 2028
- Top 50 Orphan Designated Cancer Drug Sales Forecast Till 2028
- Top 50 Drugs Account For > 70% Of Global Orphan Cancer Drug Market
- Top 50 Drugs Pricing, Dosage, Patent Insight
- Orphan Designated Cancer Drug Clinical Trials Insight by Company, Country & Indication On More Than 400 Drugs
Download Report: https://www.kuickresearch.com/report-orphan-cancer-rare-cancer-market
An orphan disease is generally defined as a condition affecting fewer than 7.5 people in 10,000 or fewer than 200,000 in the US, or fewer than 5 in 10,000 in the European Union. Among all orphan disease, the prevalence of rare cancers is increasing at high rates which are mainly attributed to rising geriatric population due to availability of better medical facilities, sudden shift to sedentary lifestyle, and increased exposure to carcinogens. Owing to increase in incidences, there is huge demand of targeted drugs in its management which can overcome the limitations of already approved drugs and demonstrated high efficacy. Since 1983, US orphan drug act aims to stimulate the investment for the development of therapies in rare cancers. The act is associated with several incentives including 7 year marketing exclusivity, tax credit for clinical trials, protocol assistance, fee waiver, and others which encourage pharmaceutical investment in this segment.
Currently, a cocktail of rare cancer drugs have been approved in the market which have demonstrated encouraging response. The major drugs in the market are Herceptin, Keytruda, Yervoy, Opdivo, Zynlonta, Polivy, Tagrisso, Xalkoti, Lumakras, and others. Apart from this, various other drugs have been designated orphan for the management of rare diseases and are currently undergoing clinical trials and are expected to enter the market in the near future. For instance, Daiichi Sankyo has also submitted new drug application (NDA) to Japan’s MHLW for valemetostat, a potential first in class dual inhibitor of EZH1 and EZH2 for the management of patients with relapsed/refractory adult T cell leukemia/lymphoma (ATL). The drug has received orphan drug designation from Japan MHLW.
Currently, the market is mainly dominated by immunotherapeutic drugs particularly Keytruda, Herceptin, Yervoy, Opdivo, Blincyto, and others. Since their entry into the market, these drugs have shown huge adoption rates which are mainly due to their targeted nature in the management of disease. Apart from this, the availability of biosimilars of few drugs whereas patent exclusivity others during the forecast period is another factor boosting their growth in the market. The advent of biosimilars boosts accessibility of the drug as well as increases the competition among pharmaceutical giants.
Currently, several clinical trials are ongoing which are evaluating novel orphan designated drugs for the management of rare cancers. US is currently occupying more than 50% share in the clinical trials which is mainly attributed to presence of various research centers in the region associated with favorable government policies which boost the investment in this domain. Further, increasing awareness for rare cancer among population, favorable reimbursement policies, and presence of key players in the market also boosts the clinical trials in the region. The major key players in US orphan cancer drugs market are Pfizer, Amgen, Roche, Novartis, Genentech, Eli Lilly, Gilead Sciences and several others. In addition to this, these pharmaceutical companies have also developed special co-pay programs like Amgen 360, which helps in reducing the overall cost of therapy.
As per report findings, the global orphan cancer drug market is expected to surpass US$ 150 Billion by 2028 which is mainly attributed to huge research and development investments in this field, and presence of robust pipeline of orphan designated drugs in clinical trials which are expected to gain approval during the forecast period. Our report provide insights into leading 50 orphan cancer drugs along with their patent, price, dosage, and sales analysis. These top 50 drugs are occupying more than 75% share in the overall market. Apart from this, it also provides insights into ongoing clinical trials in the market across various phases. The market is further segmented on the basis of region and indications.
Contact:
Neeraj Chawla
Kuick research
Research Head
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com